Summit Therapeutics (SMMT) Stock Price, News & Analysis

Company Overview

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Key Stats

• Today's Range: $18.11 to $19.25
• 50-Day Range: $18.31 to $31.93
• 52-Week Range: $1.89 to $33.89
• Volume: 1.41 million shs
• Average Volume: 3.58 million shs
• Market Capitalization: $14.00 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $34.75
• Consensus Rating: Moderate Buy

Summit Therapeutics Stock Analysis - MarketRank™

Summit Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 693rd out of 965 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Summit Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Summit Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Summit Therapeutics are expected to decrease in the coming year, from ($0.30) to ($0.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Summit Therapeutics is -67.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Summit Therapeutics is -67.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Summit Therapeutics has a P/B Ratio of 32.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.31% of the outstanding shares of Summit Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Summit Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Summit Therapeutics has recently increased by 10.29%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Summit Therapeutics does not currently pay a dividend.

Dividend Growth

Summit Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.31% of the outstanding shares of Summit Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Summit Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Summit Therapeutics has recently increased by 10.29%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.62

News Sentiment

Summit Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Summit Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 22 people have searched for SMMT on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.

MarketBeat Follows

Only 30 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Summit Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

88.30% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 4.61% of the stock of Summit Therapeutics is held by institutions.

SMMT Stock Analysis - Frequently Asked Questions

How have SMMT shares performed this year?

Summit Therapeutics' stock was trading at $2.61 at the beginning of 2024. Since then, SMMT shares have increased by 627.2% and is now trading at $18.98.
View the best growth stocks for 2024 here.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.09. The firm earned $6.12 million during the quarter.

When did Summit Therapeutics IPO?

Summit Therapeutics (SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.

Who are Summit Therapeutics' major shareholders?

Top institutional investors of Summit Therapeutics include Baker BROS. Advisors LP (3.31%), FMR LLC (1.13%), State Street Corp (0.47%) and Geode Capital Management LLC (0.42%). Insiders that own company stock include Robert W Duggan, Ankur Dhingra and Mahkam Zanganeh.
View institutional ownership trends.

How do I buy shares of Summit Therapeutics?

Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Summit Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Summit Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 11/18/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/18/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SMMT
• CUSIP: N/A
• CIK: 1599298
• Web: www.summitplc.com
• Phone: 650-460-8308
• Fax: 44-12-3544-3999
• Employees: 105
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $34.75
• High Stock Price Target: $44.00
• Low Stock Price Target: $23.00
• Potential Upside/Downside: +83.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-614,930,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -85.42%
• Return on Assets: -52.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.31
• Quick Ratio: 8.31

Sales & Book Value

• Annual Sales: $700,000.00
• Price / Sales: 19,953.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.59 per share
• Price / Book: 32.10

Miscellaneous

• Outstanding Shares: 737,450,000
• Free Float: 86,281,000
• Market Cap: $13.97 billion
• Optionable: Optionable
• Beta: -0.92